MX2013000986A - Sirna dirigido al vegfa y metodos de tratamiento in vivo. - Google Patents

Sirna dirigido al vegfa y metodos de tratamiento in vivo.

Info

Publication number
MX2013000986A
MX2013000986A MX2013000986A MX2013000986A MX2013000986A MX 2013000986 A MX2013000986 A MX 2013000986A MX 2013000986 A MX2013000986 A MX 2013000986A MX 2013000986 A MX2013000986 A MX 2013000986A MX 2013000986 A MX2013000986 A MX 2013000986A
Authority
MX
Mexico
Prior art keywords
vivo
methods
vegfa
treatment
sirna targeting
Prior art date
Application number
MX2013000986A
Other languages
English (en)
Inventor
Anja Smith
Angela Reynolds
Jon E Chatterton
Xinyu Zhang
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45527345&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2013000986(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of MX2013000986A publication Critical patent/MX2013000986A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Abstract

El factor de crecimiento endotelial vascular A (VEGFA) es una señal química producida por células que estimulan el crecimiento de nuevos vasos sanguíneos, y la sobreexpresión del VEGFA puede llevar a condiciones fisiológicas no deseadas. Mediante la identificación del nuevo siRNA y modificaciones que mejoran la habilidad de silenciar dicho siRNA in vivo, se han inventado composiciones y métodos terapéuticos para tratar los problemas asociados con dicha sobreexpresión.
MX2013000986A 2010-07-28 2011-07-26 Sirna dirigido al vegfa y metodos de tratamiento in vivo. MX2013000986A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36838510P 2010-07-28 2010-07-28
PCT/US2011/045273 WO2012015775A2 (en) 2010-07-28 2011-07-26 Sirna targeting vegfa and methods for treatment in vivo

Publications (1)

Publication Number Publication Date
MX2013000986A true MX2013000986A (es) 2013-07-03

Family

ID=45527345

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013000986A MX2013000986A (es) 2010-07-28 2011-07-26 Sirna dirigido al vegfa y metodos de tratamiento in vivo.

Country Status (16)

Country Link
US (2) US8546349B2 (es)
EP (1) EP2598639A4 (es)
JP (1) JP2013539456A (es)
KR (1) KR20130095737A (es)
CN (1) CN103068981A (es)
AR (1) AR082411A1 (es)
AU (1) AU2011282902B2 (es)
BR (1) BR112013001918A2 (es)
CA (1) CA2804847A1 (es)
CL (1) CL2013000237A1 (es)
MX (1) MX2013000986A (es)
RU (1) RU2013102545A (es)
TW (1) TW201219041A (es)
UY (1) UY33533A (es)
WO (1) WO2012015775A2 (es)
ZA (1) ZA201300531B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2943571A4 (en) * 2013-01-08 2016-11-30 Benitec Biopharma Ltd TREATMENT OF AGE-RELATED MACULAR GENERATION
CA2909442A1 (en) 2013-04-17 2014-10-23 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
TWI496595B (zh) * 2013-06-07 2015-08-21 Univ Nat Taiwan Ocean 製備魚類核醣核酸試劑之方法
EP3138293A4 (en) * 2014-04-29 2017-05-24 Microsoft Technology Licensing, LLC Encoder-side decisions for sample adaptive offset filtering
WO2016186745A1 (en) * 2015-05-15 2016-11-24 Ge Healthcare Dharmacon, Inc. Synthetic single guide rna for cas9-mediated gene editing
WO2017173327A1 (en) * 2016-03-31 2017-10-05 The Schepens Eye Research Institute, Inc. Endomucin inhibitor as an anti-angiogenic agent
GB201802404D0 (en) * 2018-02-14 2018-03-28 Univ Malta Methods
CA3096938A1 (en) * 2018-04-10 2019-10-17 Ottawa Hospital Research Institute Microrna-based compositions and methods used in disease treatment
US20220331433A1 (en) * 2019-09-06 2022-10-20 The Regents Of The University Of California Nucleic acid-mediated delivery of therapeutics
IL295445A (en) * 2020-02-10 2022-10-01 Alnylam Pharmaceuticals Inc Preparations and methods for silencing vegf-a expression

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641756A (en) 1993-07-27 1997-06-24 Hybridon, Inc. Modified VEGF oligonucleotides
US6306829B1 (en) 1995-12-08 2001-10-23 Hybridon, Inc. Modified VEGF oligonucleotides for treatment of skin disorders
US5731294A (en) 1993-07-27 1998-03-24 Hybridon, Inc. Inhibition of neovasularization using VEGF-specific oligonucleotides
US6410322B1 (en) 1993-07-27 2002-06-25 Hybridon Inc Antisense oligonucleotide inhibition of vascular endothelial growth factor expression
US6150092A (en) 1994-06-27 2000-11-21 Taogosei Company, Ltd. Antisense nucleic acid compound targeted to VEGF
US5830879A (en) 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor
JP2000501941A (ja) 1995-12-08 2000-02-22 ハイブリドン・インコーポレイテッド 修飾ｖｅｇｆアンチセンスオリゴヌクレオチド
BR9708701A (pt) 1996-04-17 2000-01-04 Hoechst Marion Roussel De Gmbh Inibidores anti-sense de expressão do fator de crescimento endotelial vascular.
WO1998027425A1 (en) 1996-12-19 1998-06-25 Isis Pharmaceuticals, Inc. Large-scale purification of full length oligonucleotides by solid-liquid affinity extraction
JPH1142091A (ja) 1997-07-25 1999-02-16 Toagosei Co Ltd アンチセンス核酸化合物
AUPP249298A0 (en) * 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
EP1089764B1 (en) 1998-06-10 2004-09-01 Biognostik Gesellschaft für biomolekulare Diagnostik mbH Stimulating the immune system
WO2000027414A2 (en) 1998-11-06 2000-05-18 Basf Aktiengesellschaft Inhibition of the formation of vascular hyperpermeability
EP1325121A2 (en) 2000-10-13 2003-07-09 Institut de Cardiologie de Montreal Antisense oligonucleotide directed toward mammalian vegf receptor genes and uses thereof
WO2002085309A2 (en) 2001-04-24 2002-10-31 Epigenesis Pharmaceuticals, Inc. Composition, formulations & kits for treatment of respiratory & lung disease with anti-sense oligonucleotides & a bronchodilating agent
WO2002085308A2 (en) 2001-04-24 2002-10-31 Epigenesis Pharmaceuticals, Inc. Antisense and anti-inflammatory based compositions to treat respiratory disorders
US20050148530A1 (en) * 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US7517864B2 (en) * 2001-05-18 2009-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
WO2003070910A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
CA2448320A1 (en) 2001-05-29 2002-12-05 Sirna Therapeutics, Inc. Ribozyme based treatment of female reproductive diseases
FR2832154B1 (fr) 2001-11-09 2007-03-16 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
AU2003207708A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
US7148342B2 (en) * 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
JP2006507841A (ja) 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ
US20100113307A1 (en) 2002-11-14 2010-05-06 Dharmacon, Inc. siRNA targeting vascular endothelial growth factor (VEGF)
WO2004076639A2 (en) * 2003-02-26 2004-09-10 Wyeth Use of gene expression profiling in the diagnosis and treatment of lupus nephritis and systemic lupus erythematosus
JP4605799B2 (ja) * 2003-04-02 2011-01-05 ダーマコン， インコーポレイテッド Ｒｎａ干渉において使用するための修飾ポリヌクレオチド
JP2008167739A (ja) * 2006-06-14 2008-07-24 National Institute Of Advanced Industrial & Technology Ｒｎａ干渉効果が高い修飾型二本鎖ｒｎａ
WO2008036825A2 (en) * 2006-09-22 2008-03-27 Dharmacon, Inc. Duplex oligonucleotide complexes and methods for gene silencing by rna interference
WO2008045576A2 (en) * 2006-10-12 2008-04-17 Yijia Liu Compositions and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases
WO2008109362A1 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting vegf gene expression and uses thereof
US20100216865A1 (en) * 2007-09-12 2010-08-26 Elias Jack A MicroRNA COMPOSITIONS IN THE TREATMENT OF VEGF-MEDIATED DISORDERS
US8188060B2 (en) 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
WO2009111658A2 (en) 2008-03-05 2009-09-11 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of eg5 and vegf genes
NZ593743A (en) * 2008-12-04 2012-07-27 Opko Ophthalmics Llc Compositions and methods for selective inhibition of pro-angiogenic vegf isoforms

Also Published As

Publication number Publication date
CL2013000237A1 (es) 2014-03-21
US9150862B2 (en) 2015-10-06
RU2013102545A (ru) 2014-09-10
WO2012015775A2 (en) 2012-02-02
AU2011282902B2 (en) 2015-01-29
KR20130095737A (ko) 2013-08-28
CA2804847A1 (en) 2012-02-02
AU2011282902A1 (en) 2013-01-31
BR112013001918A2 (pt) 2016-05-24
EP2598639A4 (en) 2014-08-13
UY33533A (es) 2012-02-29
US8546349B2 (en) 2013-10-01
ZA201300531B (en) 2014-03-26
CN103068981A (zh) 2013-04-24
US20140031414A1 (en) 2014-01-30
US20120029051A1 (en) 2012-02-02
JP2013539456A (ja) 2013-10-24
AR082411A1 (es) 2012-12-05
TW201219041A (en) 2012-05-16
WO2012015775A3 (en) 2012-08-09
EP2598639A2 (en) 2013-06-05

Similar Documents

Publication Publication Date Title
MX2013000986A (es) Sirna dirigido al vegfa y metodos de tratamiento in vivo.
MX2019005130A (es) Inhibidores de dpp-iv, tales como la linagliptina, y composiciones farmaceuticas o combinaciones que comprenden los mismos, para usarse en el tratamiento de pacientes diabeticos tipificados geneticamente.
WO2011002239A3 (ko) 포유류의 유핵세포에서 유래된 마이크로베시클 및 이의 용도
WO2012002759A3 (ko) 세포의 원형질체에서 유래한 마이크로베시클 및 이의 용도
MX346145B (es) Composición de sistema de suministro de arnsi in vivo basado en péptidos.
NZ612455A (en) Human milk oligosaccharides to promote growth of beneficial bacteria
MX340515B (es) Terapia antidiabética vasoprotectora y cardioprotectora.
EA201300669A1 (ru) Замещенные 1-бензилциклоалкилкарбоновые кислоты и их применение
MX2012010226A (es) Uso de inhibidores de erbb3 en el tratamiento de canceres de mama triple negativos y de tipo basal.
MX2011013781A (es) Anticuerpos anti-vegf y sus usos.
EP2626427A3 (en) Sirna conjugate and preparation method thereof
WO2010065671A3 (en) Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
WO2012170776A3 (en) Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy
WO2011106376A3 (en) Use of microvesicles in the treatment of medical conditions
WO2009151907A3 (en) Compositions and methods for using cells to treat heart tissue
EA201590747A1 (ru) Способы лечения с использованием аденовируса
MX2010006650A (es) Materiales y metodos para el tratamiento de proliferacion vascular ocular patologica.
NZ608734A (en) Bone marrow derived cd271 precursor cells for cardiac repair
GEP201706716B (en) Optimised subcutaneous therapeutic agents
MX348758B (es) Derivados de sanglifehrina y metodos para su produccion.
MX2014013380A (es) Usos de cxcl17, un nuevo marcador de quimiocinas de enfermedad pulmonar y gastrointestinal humana.
NZ702666A (en) A method of weight reduction
WO2010124239A3 (en) Genetic polymorphisms associated with clinical outcomes of topoisomerase inhibitor therapy for cancer
WO2012058462A3 (en) Combination therapy for the treatment of cancer
CN102533982A (zh) 人klf8基因在肿瘤治疗中的新用途

Legal Events

Date Code Title Description
FA Abandonment or withdrawal